OCTOBER 2023LIFE SCIENCES REVIEW6The biosimilar sector is gaining significant traction globally, presenting an opportunity for companies to thrive through innovation in commercial strategies, portfolio management, and accelerated research and development. With the evolution of regulatory landscapes, biosimilar prospects expand, and pricing dynamics become more agile, prompting companies to offer early discounts and rebates for specific channels and key accounts. A thriving biosimilar market promises to expand patient access to advanced yet affordable treatments and curb healthcare expenses. Achieving success in this environment hinges on balancing commercial approaches across diverse channels, necessitating a profound understanding of decision-making dynamics among physicians, patients, payers, and providers to tailor strategies accordingly.According to market research, the global biosimilar market size was exhibited at $25.12 bn in 2022, and it is expected to surpass around $126.01 bn by 2032, at a CAGR of 17.6 percent. The global biosimilar market thrives due to its cost-effective approach to treating prevalent chronic diseases. Data analytics is pivotal in developing, evaluating, and obtaining FDA approval for biosimilars. These analyses, facilitated by cloud-based or AI-driven statistical tools, are essential for assessing biosimilars. Machine learning can help identify potential risk factors for immune reactions, enhancing biosimilar safety and cost-effectiveness.This Life Sciences Review Europe edition brings the key developments in the biosimilars sector through thought leadership articles from Marc de Garidel, CEO and Interim Chairman, Abivax, and Piero Rijli, Corporate Director, Regulatory Activities and Market Access, MENARINI Group.Marc de Garidel discusses the trends in the life science industry, focusing on the impact of technological advancements and the shift toward precision medicine. Piero Rijli navigates the implications of antimicrobial resistance (AMR), which poses a significant threat to the future of human health, and the need for raising awareness and conducting economic evaluations at the population level to account for externalities related to antibiotic use.This edition features stories from companies that bring their solutions and services to this space.In this edition featuring the Top Biosimilar Services Providers in Europe 2023, we hope you find the appropriate company suited to your business requirements.Let us know your thoughts.EDITORIALAdvancing Biosimilars for Better Healthcare Outcomes Copyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy Williamsoctober - 23 - 2023, Vol 04, Issue - 42 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersRonald DonovanVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 5 | Page 7 >